A clinical case of thrombotic syndrome in a patient with chronic kidney disease in the terminal stage

Oleksandra  Rudenko; Olena  Karpenko; Igor  Paliienko; Victoria  Yerokhovych

doi:10.32345/USMYJ.2(154).2025.23-29

Oleksandra Rudenko student of the  Faculty of Medicine of the Bogomolets National Medical University , Kyiv, Ukraine https://orcid.org/0009-0004-3132-4689
Olena Karpenko PhD, Associate Professor of the Department of Nephrology and Urology of the Postgraduate Education Institute of the Bogomolets National Medical University , Kyiv, Ukraine https://orcid.org/0000-0001-8952-8482
Igor Paliienko assistant professor, graduate student of the Department of Endocrinology, Bogomolets National Medical University, Kyiv, Ukraine http://orcid.org/0000-0001-9939-7316
Victoria Yerokhovych MD, Professor of the Department of Propedeutics of Internal Medicine №2 of the Bogomolets National Medical University , Kyiv, Ukraine https://orcid.org/0000-0002-9800-9796

DOI: https://doi.org/10.32345/USMYJ.2(154).2025.23-29

Keywords: Chronic Kidney Disease; Thrombosis; Hyperhomocysteinemia; Hemodialysis; genetic analysis

Abstract

thrombotic syndrome is a frequent problem in patients with kidney damage, especially in the terminal stage, when the issue of vascular access for the hemodialysis procedure is extremely relevant. The clinical case presented by us with repeated thrombosis of an arteriovenous fistula demonstrates the algorithm of diagnostic search for the causes of thrombotic syndrome. The purpose of the work is to draw the attention of doctors to modern diagnostic tests for thrombotic syndrome with the help of genetic tests, to report a clinical case of vascular access thrombosis in a patient with chronic kidney disease in the terminal stage against the background of a combination of mutations in the genes of the hemostasis system and an increase in blood homocysteine.

References

Grupp C, Troche-Polzien Stock IJ, Bramlage C, Müller G A, Koziolek M (2019) Thrombophilic risk factors in hemodialysis: Association with early vascular access occlusion and patient survival in long-term follow-up. PLOS ONE. https://doi.org/10.1371/journal.pone.0222102

Палієнко І.А., Карпенко О.В., Красюк І.В., Кравчук А.Д., Миколаєнко Ю.В., Руденко О.А. Гіпергомоцистеїнемія – ризик-фактор судинних ускладнень у хворих на хронічну хворобу нирок Нирки (Kidneys). 2024; №1(том 13). С.68-71. https://doi.org/10.22141/2307-1257.13.1.2024.443

Zhang Y, Yi J, Zhang R , Peng Y , Dong J , Sha L (2022) Risk Factors for Arteriovenous Fistula Thrombus Development: A Systematic Review and Meta-Analysis. Kidney Blood Press Res https://doi.org/10.1159/000526768

Fekih-Mrissa N, Sayeh A, Baffoun A, Beji M, Mrad M, Hmida J, Nsiri B (2016) Association Between Thrombophilic Gene Mutations and the Risk of Vascular Access Thrombosis in Hemodialysis Patients. Therapevtic Apheresis and Dialisis https://doi.org/10.1111/1744-9987.12379

Hyperhomocysteinemia as an Independent Risk Factor for Coronary Heart Disease. Comparison with Conventional Risk Factors. Muzaffar R., Khan M. A., Mushtaq M. H., Nasir M., Khan A. I. ul Haq, J. Muhammad Braz. J. Biol. 2023, 83 https://doi.org/10.1590/1519-6984.249104

Hyperhomocysteinemia in Adult Patients: A Treatable Metabolic Condition González-Lamuño D., Arrieta-Blanco F. J., Fuentes E. D., Forga-Visa M. T., Morales-Conejo M., Peña-Quintana L., Vitoria-Miñana I. Nutrients. 2024; 16(1): 135 doi: 10.3390/nu16010135

Homocysteine as a predictor and prognostic marker of atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Habib S.S., Al-khlaiwi T., Almushawah A., Alsomali A., Habib S.A. Eur Rev Med Pharmacol Sci 2023; 27 (18): 8598-8608 DOI: 10.26355/eurrev_202309_33784

Association of hyperhomocysteinemia and chronic kidney disease in the general population: a systematic review and meta-analysis. Chen W., Feng J., Ji P., Liu Y., Wan H., Zhang J. BMC Nephrology (2023) 24:247 https://doi.org/10.1186/s12882-023-03295-y

Plasma Homocysteine Levels and Cardiovascular Events in Patients With End-Stage Renal Disease: A Systematic Review. AlSolami A.A., Almalki A.A., Alhedyan S.Y., Alghamdi A., Alzahrani S.M., Dause W.R., Hamdi F.A., Howladar M.T., Ibrahim I.A. Cureus. 2023 Jun; 15(6): e40357. .doi: 10.7759/cureus.40357

Arterial thrombosis triggered by methotrexate-induced hyperhomocysteinemia in a systemic lupus erythematosus patient with antiphospholipid antibodies Schiavi C., Marri L., Negrini S. Thromb J. 2023; 21: 113. doi: 10.1186/s12959-023-00557-5

Hellmich B, Sanchez-Alamo B, Schirmer J H et al.( 2022) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis http://dx.doi.org/10.1136/ard-2022-223764

Barbhaiya M, Zuily S, Naden R et al (2023) 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol. https://doi.org/10.1002/art.42624

Kaye AD, Jeha G M., Pham A D et al. (2020) Folic Acid Supplementation in Patients with Elevated Homocysteine Levels. Advances in Therapy. https://doi.org/10.1007/s12325-020-01474-z